ICON to Acquire MediMedia Pharma Solutions

February 2, 2015
Company Press Release
Applied Clinical Trials

   Dublin, Ireland, February 2nd, 2015 – ICON plc (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has agreed, subject to certain customary closing conditions, to acquire MediMedia Pharma Solutions for a cash consideration of $120 million. MediMedia Pharma Solutions is division of MediMedia USA and is owned by Vestar Capital Partners.   The acquisition strengthens ICON’s expertise in scientific communications and market access and, together with ICON’s existing Commercialisation and Outcomes practices, creates the industry’s leading integrated scientific communications and market access solution.   Headquartered in Yardley, Pennsylvania, MediMedia Pharma Solutions includes MediMedia Managed Markets andComplete Healthcare Communications. MediMedia Managed Markets is a leading provider of strategic payer-validated market access solutions. Complete Healthcare Communications is one of the leading medical and scientific communication agencies working with medical affairs, commercial and brand development teams within life science companies. MediMedia Pharma Solutions has supported hundreds of development launches and in-market products, spanning over 40 therapeutic classes.    Commenting on the acquisition, Ciaran Murray, ICON CEO, said: “The need to demonstrate and communicate the value of new medicines is an important global healthcare trend. Through ICON’s market leading commercialisation and outcomes group we are supporting our customers to maximise the value of their new drugs. Our acquisition of MediMedia Pharma Solutions deepens the expertise of this group and brings us outstanding scientific and medical communications capabilities.”   Tim Search, President of MediMedia Pharma Solutions, commented, “The combination of the commercial, scientific, and market access expertise of MediMedia Pharma Solutions and ICON creates an unparalleled offering that can inform product investment decisions and establish and communicate product value. With the shift to evidence-based medicine and value-based pricing, we are excited about the expanded expertise and capabilities our relationship with ICON brings to our combined customers.”